We investigate the antinociceptive effect of intrathecal and intraperitoneal tempol administration in a rat model of chronic constriction injury (CCI)-induced neuropathic pain and explore the underlying antinociceptive mechanisms of tempol. Rats were randomly assigned to four groups (n = 8 per group): sham group, CCI group, Tem1 group (intrathecal injection of tempol), and Tem2 group (intraperitoneal injection of tempol). Neuropathic pain was induced by CCI of the sciatic nerve. Tempol was intrathecally or intraperitoneally administered daily for 7 days beginning on postoperative day one. The mechanical withdrawal threshold and thermal withdrawal latency were tested on preoperative day 3 and postoperative days 1, 3, 5, 7, 10, 14, and 21. Structural changes were examined by hematoxylin and eosin staining, toluidine blue staining, and electron microscopy. Malondialdehyde (MDA) and superoxide dismutase (SOD) levels were determined using the thiobarbituric acid and nitroblue tetrazolium methods, respectively. Nerve growth factor (NGF) expression levels were determined by immunohistochemistry and Western blot. Intrathecal, but not intraperitoneal, injection of tempol produced a persistent antinociceptive effect. Intraperitoneal injection of tempol did not result in high enough concentration of tempol in the cerebrospinal fluid. Intrathecal, but not intraperitoneal, injection of tempol inhibited CCI-induced structural damage in the spinal cord reduced MDA levels, and increased SOD activities in the spinal cord. Furthermore, intrathecal, but not intraperitoneal, injection of tempol further downregulated the expression of NGF in the spinal cord following CCI, and this effect was blocked by p38MAPK inhibitor. Intrathecal injection of tempol produces antinociceptive effects and reduces CCI-induced structural damage in the spinal cord by increasing SOD activities and downregulating the expression of NGF via the p38MAPK pathway. Intraperitoneal administration of tempol does not exhibit antinociceptive effects.
This work was supported by the Medjaden Academy & Research Foundation for Young Scientists and BBraun Anesthesia Scientific Research Fund (Grant Nos. MJR20150037 and BBF 2012-012).We thank Dr. Lingxin Meng for supporting this study.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Beaudry F, Girard C, Vachon P (2007) Early dexamethasone treatment after implantation of a sciatic-nerve cuff decreases the concentration of substance P in the lumbar spinal cord of rats with neuropathic pain. Can J Vet Res 71:90–97PubMedPubMedCentralGoogle Scholar
Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87–107CrossRefPubMedGoogle Scholar
Blonder JM, McCalden TA, Hsia CJ, Billings RE (2000) Polynitroxyl albumin plus tempol attenuates liver injury and inflammation after hepatic ischemia and reperfusion. Life Sci 67:3231–3239CrossRefPubMedGoogle Scholar
Cahill CM, Dray A, Coderre TJ (2003) Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 45:543–552CrossRefPubMedGoogle Scholar
Cao YY, Ding XD, Meng LX, Zhao BS (2014) Effects of tempol preconditioning on the expression level of HIF-α and VEGF after brain injure induced by cardiac arrest in rats. Guandong Med J 35:497–500Google Scholar
Chatterjee PK, Cuzzocrea S, Brown PA, Zacharowski K, Stewart KN, Mota-Filipe H, Thiemermann C (2000) Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 58:658–673. doi:10.1046/j.1523-1755.2000.00212.xCrossRefPubMedGoogle Scholar
Gwak YS, Hassler SE, Hulsebosch CE (2013) Reactive oxygen species contribute to neuropathic pain and locomotor dysfunction via activation of CamKII in remote segments following spinal cord contusion injury in rats. Pain 154:1699–1708. doi:10.1016/j.pain.2013.05.018CrossRefPubMedGoogle Scholar
Hahn SM et al (1992) Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 52:1750–1753PubMedGoogle Scholar
Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57–68CrossRefPubMedGoogle Scholar
Kato N, Yanaka K, Hyodo K, Homma K, Nagase S, Nose T (2003) Stable nitroxide Tempol ameliorates brain injury by inhibiting lipid peroxidation in a rat model of transient focal cerebral ischemia. Brain Res 979:188–193CrossRefPubMedGoogle Scholar
Khalil Z, Liu T, Helme RD (1999) Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. Pain 79:31–37CrossRefPubMedGoogle Scholar
Liu HX, Zhang JJ, Zhang L, Liu H (2013) Effects of tempol on white matter lesions and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Zhonghua yi xue za zhi 93:1330–1334PubMedGoogle Scholar
Patel SP, Sullivan PG, Pandya JD, Rabchevsky AG (2009) Differential effects of the mitochondrial uncoupling agent, 2,4-dinitrophenol, or the nitroxide antioxidant, Tempol, on synaptic or nonsynaptic mitochondria after spinal cord injury. J Neurosci Res 87:130–140. doi:10.1002/jnr.21814CrossRefPubMedGoogle Scholar
Zhao BS, Ding YY, Wang H, Han G, Meng LX (2013) Effects of hyperbaric oxygen postconditioning of microglia on activation in rats model of neuropathic pain. Int J Anesth Resus 34:546–548Google Scholar
Zhao BS, Meng LX, Ding YY, Cao YY (2014a) Hyperbaric oxygen treatment produces an antinociceptive response phase and inhibits astrocyte activation and inflammatory response in a rat model of neuropathic pain. J Mol Neurosci 53:251–261. doi:10.1007/s12031-013-0213-3CrossRefPubMedGoogle Scholar
Zhao BS, Meng LX, Tan YH, Song XR (2014b) Effects hyperbaric oxygen treatment on expression of nerve growth factor in spinal cord of rats with neuropathic pain. Chin J Anesthesiol 34:800–803Google Scholar